COLO-PREVENT
https://coloprevent.co.uk/ Add to Contact List

Clinical samples collected from participants in COLO-PREVENT, a world first trial platform in prevention that consists of a main phase 3 study comparing aspirin alone versus aspirin plus metformin, and a phase 2 signal seeking trial of resveratrol, conducted in high-risk patients recruited through the NHS Bowel Cancer Screening Programme. The phase 3 trial is a 3 year intervention with aspirin/metformin and the phase 2 trial is a 1 year intervention comparing low and high dose resveratrol against placebo. The following samples are being collected and are being stored and analysed as part of the COLO-PREVENT translational programme: 1) Plasma and serum collected at baseline, 6 monthly intervals and the end of the trial. 2) Fresh frozen and formalin fixed paraffin embedded biopsies of normal rectal tissue taken at the end of the trial. 3) FFPE diagnostic samples of colorectal polyps taken as part of the initial screening colonoscopy and any polyps removed during the surveillance colonoscopy at the end of the trial. 4) Faecal samples collected using a FIT kit, at baseline, 1 year (for the main trial) and study end. These will be completely used for microbiome analysis. 5) Urine samples from a proportion of patients in the phase 2 resveratrol signal seeking trial.

Contact Information

Last Updated: 05/01/2024

Annual Statistics